688506 百利天恒
已收盘 09-30 15:00:00
资讯
新帖
简况
百利天恒(688506.SH)：T-Bren纳入突破性治疗品种名单
智通财经 · 09-27
百利天恒(688506.SH)：T-Bren纳入突破性治疗品种名单
百利天恒最新公告：注射用BL-M12D1获临床试验批准通知书
证券之星 · 09-27
百利天恒最新公告：注射用BL-M12D1获临床试验批准通知书
百利天恒最新公告：宜泽康®纳入突破性治疗品种名单
证券之星 · 09-27
百利天恒最新公告：宜泽康®纳入突破性治疗品种名单
百利天恒（688506）披露提前归还临时补充流动资金的募集资金公告，9月24日股价下跌3.62%
证券之星 · 09-24
百利天恒（688506）披露提前归还临时补充流动资金的募集资金公告，9月24日股价下跌3.62%
百利天恒跌5.33% 招商证券在历史大顶发研报强烈推荐
中金财经 · 09-22
百利天恒跌5.33% 招商证券在历史大顶发研报强烈推荐
百利天恒子公司获施贵宝2.5亿美元里程碑付款，伊扎-布伦协议推进顺利
美股速递 · 09-21
百利天恒子公司获施贵宝2.5亿美元里程碑付款，伊扎-布伦协议推进顺利
百利天恒(688506.SH)：宜泽康®联合PD-1纳入突破性治疗品种名单
智通财经 · 09-21
百利天恒(688506.SH)：宜泽康®联合PD-1纳入突破性治疗品种名单
百利天恒药业涨6.41%，开源证券三周前给出“买入”评级
证券之星 · 09-21
百利天恒药业涨6.41%，开源证券三周前给出“买入”评级
百利天恒(688506.SH)子公司拟500万美元投资创新药企业Connexus Therapeutics
智通财经 · 09-17
百利天恒(688506.SH)子公司拟500万美元投资创新药企业Connexus Therapeutics
百利天恒最新公告：全资子公司拟500万美元投资ConnexusTherapeutics
证券之星 · 09-17
百利天恒最新公告：全资子公司拟500万美元投资ConnexusTherapeutics
百利天恒子公司拟投资500万美元 收购Connexus Therapeutics 7.91%股权
美股速递 · 09-17
百利天恒子公司拟投资500万美元 收购Connexus Therapeutics 7.91%股权
百利天恒：拟与关联人以现金500万美元投资Connexus
格隆汇 · 09-17
百利天恒：拟与关联人以现金500万美元投资Connexus
9月14日百利天恒涨5.61%，中欧医疗健康混合A基金重仓该股
证券之星 · 09-14
9月14日百利天恒涨5.61%，中欧医疗健康混合A基金重仓该股
百利天恒涨5.61%，开源证券二周前给出“买入”评级
证券之星 · 09-14
百利天恒涨5.61%，开源证券二周前给出“买入”评级
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于注射用T-Bren（HER2 ADC）在HER2阳性乳腺癌新辅助治疗的III期临床试验完成首例受试者入组的公告》
证券之星 · 09-14
股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于注射用T-Bren（HER2 ADC）在HER2阳性乳腺癌新辅助治疗的III期临床试验完成首例受试者入组的公告》
百利天恒最新公告：T-Bren联合帕妥珠单抗III期临床试验完成首例受试者入组
证券之星 · 09-13
百利天恒最新公告：T-Bren联合帕妥珠单抗III期临床试验完成首例受试者入组
每周股票复盘：百利天恒（688506）宜泽康III期临床完成首例入组
证券之星 · 09-13
每周股票复盘：百利天恒（688506）宜泽康III期临床完成首例入组
百利天恒（688506）披露宜泽康®III期临床试验完成首例受试者入组，9月10日股价上涨2.2%
证券之星 · 09-10
百利天恒（688506）披露宜泽康®III期临床试验完成首例受试者入组，9月10日股价上涨2.2%
百利天恒：宜泽康III期临床试验完成首例受试者入组
同花顺 · 09-09
百利天恒：宜泽康III期临床试验完成首例受试者入组
百利天恒跌3.34% 招商证券在历史大顶发研报强烈推荐
中金财经 · 09-08
百利天恒跌3.34% 招商证券在历史大顶发研报强烈推荐
公司概况
公司名称：
四川百利天恒药业股份有限公司
所属行业：
医药制造业
上市日期：
2023-01-06
主营业务：
四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是丙泊酚乳状注射液、吸入用七氟烷、丙泊酚中/长链脂肪乳注射液、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。
发行价格：
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":242,"timestamp":1790751600000,"preClose":236,"halted":0,"volume":1493787,"delay":0,"changeRate":0.0254,"floatShares":413000000,"shares":413000000,"eps":-3.8096,"marketStatus":"已收盘","change":6,"latestTime":"09-30 15:00:00","open":234.36,"high":246.88,"low":234.36,"amount":361000000,"amplitude":0.0531,"askPrice":242.15,"askSize":2,"bidPrice":242,"bidSize":6,"shortable":0,"etf":0,"ttmEps":-3.8096,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":236,"symbolType":"stock_kcb","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":259.6,"lowLimit":212.4,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":21.67,"roa":"--","roe":"--","epsLYR":-2.61,"committee":0.166667,"marketValue":99915000000,"turnoverRate":0.0036,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-08。","afterMarket":{"amount":0,"volume":0,"close":242,"buyVolume":0,"sellVolume":400,"time":1790753637746,"indexStatus":"已收盘 09-30 15:30:00","preClose":236},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1791187200000,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":99915000000},"requestUrl":"/m/hq/s/688506/wiki","defaultTab":"wiki","newsList":[{"id":"2670405636","title":"百利天恒(688506.SH)：T-Bren纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2670405636","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670405636?lang=zh_cn&edition=full","pubTime":"2026-09-27 19:31","pubTimestamp":1790508687,"startTime":"0","endTime":"0","summary":"除此次新纳入外，2025年11月，T-Bren用于既往经一线抗HER2治疗及一线标准化疗方案治疗失败的HER2阳性局部晚期或转移性胃癌或胃食管结合部腺癌患者方案已被药审中心纳入突破性治疗品种名单并完成公示。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670033444","title":"百利天恒最新公告：注射用BL-M12D1获临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2670033444","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670033444?lang=zh_cn&edition=full","pubTime":"2026-09-27 16:41","pubTimestamp":1790498483,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司近日收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》，自主研发的创新生物药注射用BL-M12D1(ADC)的临床试验获得批准，同意本品单药开展在复发性或难治性血液系统恶性肿瘤的临床试验。该药品是与宜泽康(伦康依隆妥单抗，BL-B01D1/iza-bren)共享同一“连接子+毒素”平台的ADC药物。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092700001056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670345403","title":"百利天恒最新公告：宜泽康®纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2670345403","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670345403?lang=zh_cn&edition=full","pubTime":"2026-09-27 16:41","pubTimestamp":1790498460,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的宜泽康(伦康依隆妥单抗，BL-B01D1/iza-bren)用于既往经含铂化疗治疗失败的复发性或转移性胆道癌患者方案，已被国家药监局药审中心纳入突破性治疗品种名单，近日已完成公示。截至目前，宜泽康已有9项适应症被纳入突破性治疗品种名单，1项适应症获美国FDA突破性疗法认定。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092700001059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669466040","title":"百利天恒（688506）披露提前归还临时补充流动资金的募集资金公告，9月24日股价下跌3.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669466040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669466040?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:36","pubTimestamp":1790242590,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，百利天恒报收于239.3元，较前一交易日下跌3.62%，最新总市值为988.01亿元。公司于近日披露《关于提前归还临时补充流动资金的募集资金的公告》。公告显示，四川百利天恒药业股份有限公司于2025年9月29日召开董事会，同意使用不超过7亿元闲置募集资金暂时补充流动资金，期限自董事会批准日起不超过12个月，该资金用于创新药研发及主营业务相关生产经营。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400030432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669110433","title":"百利天恒跌5.33% 招商证券在历史大顶发研报强烈推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2669110433","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669110433?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:13","pubTimestamp":1790068390,"startTime":"0","endTime":"0","summary":"中国经济网北京9月22日讯 百利天恒(688506.SH)今日收报250.82元，跌幅5.33%。\n\n 2025年9月8日，百利天恒股价盘中创上市以来高点414.02元。\n\n 招商证券股份有限公司研究员梁广楷、许菲菲、焦玉鹏2025年9月12日发布研报《百利天恒(688506)：从双抗ADC出发 多平台布局迈向国际领先的MNC》称，给予“强烈推荐”投资评级。\n\n 国泰海通证券股份有限公司研究员余文心、廖博闻2025年9月12日发布研报《百利天恒(688506)：WCLC上公布全球BIC数据 IZA-BREN有望冲击一线市场》称，维持增持评级。\n\n (责任编辑：徐自立)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260922/32377887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1564","688506","BK0010","91194","600999","BK0028","06099","BK0012","BK0188","BK0276","BK0239","BK1147","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190206250","title":"百利天恒子公司获施贵宝2.5亿美元里程碑付款，伊扎-布伦协议推进顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=1190206250","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190206250?lang=zh_cn&edition=full","pubTime":"2026-09-21 19:17","pubTimestamp":1789989431,"startTime":"0","endTime":"0","summary":"百利天恒宣布，其下属子公司已收到来自施贵宝的2.5亿美元里程碑付款。这笔资金与双方签署的伊扎-布伦协议相关，标志着合作项目取得阶段性重大进展。百利天恒方面表示，此次里程碑付款的落实，是两家企业深化战略伙伴关系的关键一步，同时也为创新药管线的价值释放奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","LU1718418525.SGD","LU2133065610.SGD","LU2125154778.USD","IE0009355771.USD","LU0096364046.USD","LU0225771236.USD","LU1261432733.SGD","LU1868836757.USD","LU2242646821.SGD","LU1670711040.USD","LU1670710588.SGD","LU0882574055.USD","LU0456855351.SGD","LU1291159041.SGD","IE00B2B36J28.USD","LU0114720955.EUR","BK4532","LU0985481810.HKD","LU1236620750.USD","IHE","LU1571399168.USD","FTXH","IE00BFXG1179.USD","LU1430594728.SGD","LU1983299246.USD","LU0868494617.USD","LU2596442595.SGD","BK4581","LU0061475181.USD","IE0002141913.USD","BK0239","LU0237698245.USD","LU1868836591.USD","BK4585","LU1074936037.SGD","LU2242652126.USD","LU2360032135.SGD","BK4534","IE00BSNM7G36.USD","LU1585245621.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU1670711123.USD","LU1093756168.USD","IE00BJT1NW94.SGD","LU0432979614.USD","LU1093756325.SGD","LU1868837300.USD","LU2125154935.USD","LU1032466523.USD","BMY","LU1868836914.USD","LU1323610961.USD","LU1989771016.USD","BK4559","LU0321505439.SGD","LU0321505868.SGD","LU1670710661.SGD","LU1868837136.USD","LU1883839398.USD","LU0267386448.USD","LU0306806265.USD","BK4588","LU1236620834.HKD","688506","BK4007","LU0306807586.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669738150","title":"百利天恒(688506.SH)：宜泽康®联合PD-1纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2669738150","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669738150?lang=zh_cn&edition=full","pubTime":"2026-09-21 19:13","pubTimestamp":1789989238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司自主研发的全球首创(First-in-class)、新概念(New concept)、全球首个且唯一获批上市的EGFR×HER3双抗 ADC 宜泽康®(伦康依隆妥单抗，BL-B01D1/iza-bren)联合PD-1 单抗用于PD-L1阳性局部复发不可切除或转移性三阴性乳腺癌的一线治疗方案已被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，近日已完成公示，本次系是宜泽康®相关治疗方案被药审中心纳入突破性治疗品种名单的首个一线适应性突破疗法。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498890.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百利天恒(688506.SH)：宜泽康®联合PD-1纳入突破性治疗品种名单","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669955159","title":"百利天恒药业涨6.41%，开源证券三周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669955159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669955159?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:42","pubTimestamp":1789980163,"startTime":"0","endTime":"0","summary":"今日百利天恒药业涨6.41%，收盘报264.93元。2026年8月28日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《公司信息更新报告：宜泽康商业化元年开启，核心管线进入全球加速期》，该研报对百利天恒给出“买入”评级。研报中预计2026-2028年营业收入分别为24.89/23.81/32.74亿元，PS分别为44.9/47.0/34.1倍，维持“买入”评级。百利天恒药业个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","161027","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668964804","title":"百利天恒(688506.SH)子公司拟500万美元投资创新药企业Connexus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2668964804","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668964804?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:44","pubTimestamp":1789645459,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，为拓宽公司在除创新ADC药物研发平台，创新多特异性抗体药物研发平台，以及特异性增强双特异性抗体平台及创新ARC(核药)研发平台以外其他前沿技术赛道的布局，补充公司技术矩阵。公司全资子公司盘古资本拟以500万美元认购Connexus Therapeutics388.1万股A轮优先股股份，本次增资完成后，公司将持有Connexus 7.91%股权。Connexus是一家创新药企业，专注于肿瘤领域小分子药物的开发，其在研项目均处于临床前研发阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","IBBQ","91194","LNGR","LENZ","159992","BK4539","688506","06978","MEDX","BK1161","BK0239","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668611449","title":"百利天恒最新公告：全资子公司拟500万美元投资ConnexusTherapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2668611449","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668611449?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:30","pubTimestamp":1789644656,"startTime":"0","endTime":"0","summary":"百利天恒公告称，公司全资子公司盘古资本拟以500万美元认购Connexus Therapeutics388.1万股A轮优先股，增资完成后将持有其7.91%股权。Connexus是一家创新药企业，专注于肿瘤领域小分子药物的开发，其在研项目均处于临床前研发阶段。本次交易旨在通过对Connexus进行投资，使Connexus成为公司的参股公司，拓宽公司在除创新ADC药物研发平台，创新多特异性抗体药物研发平台，以及特异性增强双特异性抗体平台及创新ARC（核药）研发平台以外其他前沿技术赛道的布局，补充公司技术矩阵。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700031761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135352374","title":"百利天恒子公司拟投资500万美元 收购Connexus Therapeutics 7.91%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1135352374","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135352374?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:30","pubTimestamp":1789644633,"startTime":"0","endTime":"0","summary":"百利天恒（Sichuan Biokin Pharmaceutical）近日宣布，其旗下子公司计划向Connexus Therapeutics注资500万美元。此项投资完成后，该子公司将持有Connexus Therapeutics 7.91%的股份。这一战略举措标志着百利天恒在生物医药领域的进一步布局，旨在通过资本纽带加深与国际创新药企的合作纽带。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668961524","title":"百利天恒：拟与关联人以现金500万美元投资Connexus","url":"https://stock-news.laohu8.com/highlight/detail?id=2668961524","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668961524?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:27","pubTimestamp":1789644443,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667592716","title":"9月14日百利天恒涨5.61%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667592716","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667592716?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:37","pubTimestamp":1789375069,"startTime":"0","endTime":"0","summary":"证券之星消息，9月14日百利天恒涨5.61%，收盘报252.0元，换手率0.55%，成交量2.25万手，成交额5.5亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共104家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为127.36亿元，最新净值1.8588，较上一交易日下跌2.06%，近一年下跌9.56%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400021144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","159760","688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667365926","title":"百利天恒涨5.61%，开源证券二周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2667365926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667365926?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:37","pubTimestamp":1789375058,"startTime":"0","endTime":"0","summary":"今日百利天恒涨5.61%，收盘报252.0元。2026年8月28日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《公司信息更新报告：宜泽康商业化元年开启，核心管线进入全球加速期》，该研报对百利天恒给出“买入”评级。研报中预计2026-2028年营业收入分别为24.89/23.81/32.74亿元，PS分别为44.9/47.0/34.1倍，维持“买入”评级。百利天恒个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400021140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","161027","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667687062","title":"股市必读：百利天恒新发布《四川百利天恒药业股份有限公司自愿披露关于注射用T-Bren（HER2 ADC）在HER2阳性乳腺癌新辅助治疗的III期临床试验完成首例受试者入组的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667687062","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667687062?lang=zh_cn&edition=full","pubTime":"2026-09-14 01:05","pubTimestamp":1789319113,"startTime":"0","endTime":"0","summary":"公司公告汇总四川百利天恒药业股份有限公司自愿披露关于注射用T-Bren在HER2阳性乳腺癌新辅助治疗的III期临床试验完成首例受试者入组的公告四川百利天恒药业股份有限公司自主研发的创新生物药注射用T-Bren联合帕妥珠单抗在HER2阳性乳腺癌新辅助治疗中的III期随机对照临床试验已完成首例受试者入组。该药物具有同类最佳潜力，已在全球范围内开展20项临床试验，覆盖多种HER2相关肿瘤适应症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400000447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","91194","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667689797","title":"百利天恒最新公告：T-Bren联合帕妥珠单抗III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2667689797","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667689797?lang=zh_cn&edition=full","pubTime":"2026-09-13 15:39","pubTimestamp":1789285179,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的创新生物药注射用T-Bren(HER2ADC)联合帕妥珠单抗在HER2阳性乳腺癌新辅助治疗中对比多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗的III期随机对照临床试验已完成首例受试者入组。截至目前，T-Bren正在国内外开展20项临床试验，覆盖乳腺癌、胃癌、肺癌、消化道肿瘤、泌尿系统肿瘤和妇科肿瘤等多项适应症。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300003185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","91194","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507390","title":"每周股票复盘：百利天恒（688506）宜泽康III期临床完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507390","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507390?lang=zh_cn&edition=full","pubTime":"2026-09-13 01:46","pubTimestamp":1789235173,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，百利天恒报收于238.62元，较上周的261.5元下跌8.75%。本周，百利天恒9月7日盘中最高价报263.57元。本周关注点来自公司公告汇总：宜泽康用于不可切除EGFR突变非小细胞肺癌维持治疗的III期临床试验完成首例受试者入组。来自公司公告汇总：百利天恒将参加2026年半年度科创板创新药行业集体业绩说明会，与投资者交流经营成果及发展战略。宜泽康是全球首创、新概念双抗ADC，已在中国和美国开展超45项临床试验，其中III期研究20项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666619805","title":"百利天恒（688506）披露宜泽康®III期临床试验完成首例受试者入组，9月10日股价上涨2.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666619805","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666619805?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:27","pubTimestamp":1789032452,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，百利天恒报收于245.64元，较前一交易日上涨2.2%，最新总市值为1014.18亿元。该股当日开盘240.91元，最高249.8元，最低239.34元，成交额达5.35亿元，换手率为0.53%。近日，四川百利天恒药业股份有限公司发布自愿披露公告，称其自主研发的宜泽康用于不可切除EGFR突变非小细胞肺癌同步放化疗后维持治疗的III期临床试验已完成首例受试者入组。宜泽康是全球首创、新概念双抗ADC，已在中国和美国开展超45项临床试验，其中III期研究20项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000031128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589136","title":"百利天恒：宜泽康III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589136","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666589136?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:09","pubTimestamp":1788944940,"startTime":"0","endTime":"0","summary":"每经AI快讯，9月9日，百利天恒公告称，公司自主研发的全球首创双抗ADC宜泽康用于不可切除EGFR突变非小细胞肺癌同步放化疗后维持治疗的III期临床试验已完成首例受试者入组。每日经济新闻 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260909/c679746443.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260909/c679746443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BMED","688506","IBBJ","MDTX","91194","PSYK","IBBQ","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329543","title":"百利天恒跌3.34% 招商证券在历史大顶发研报强烈推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329543","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665329543?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:36","pubTimestamp":1788860175,"startTime":"0","endTime":"0","summary":"中国经济网北京9月8日讯 百利天恒 今日收报244.56元，跌幅3.34%。 2025年9月8日，百利天恒股价盘中创上市以来高点414.02元。 招商证券股份有限公司研究员梁广楷、许菲菲、焦玉鹏2025年9月12日发布研报《百利天恒：从双抗ADC出发 多平台布局迈向国际领先的MNC》称，给予“强烈推荐”投资评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260908/32363588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0276","688506","BK0183","06099","BK0010","BK0012","BK0239","BK1147","BK1564","600999","BK0028","91194","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791199228542,"stockEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":-0.0931},{"period":"3month","weight":-0.2787},{"period":"6month","weight":-0.2281},{"period":"1year","weight":-0.3552},{"period":"ytd","weight":-0.251}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9075人(较上一季度增加16.69%)","perCapita":"45495股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是丙泊酚乳状注射液、吸入用七氟烷、丙泊酚中/长链脂肪乳注射液、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}